23/05/2024  12:19:21 Var. -2.26 Volume Denaro13:23:44 Lettera13:24:03 Capitalizzazione di mercato Dividend Y. Rapporto P/E
148.62EUR -1.50% 2
Fatturato: 297.24
147.28Quantità in denaro: 74 148.30Quantità in lettera: 37 260.4 bill.EUR - -

Descrizione business

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world's most complex and critical conditions. The company's mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
 

Consiglio di amministrazione & Consiglio di sorveglianza

CEO
Richard A. Gonzalez
Consiglio di amministrazione
Scott T. Reents, Carrie Strom, Dr. Azita Saleki-Gerhardt, Jeffrey R. Stewart, Perry C. Siatis, Rae L. Livingston, Robert A. Michael, Timothy J. Richmond, Kevin Buckbee, Nicholas Donoghoe, Tracie Haas, Thomas Hudson, Greg Miley, Elaine K. Sorg
Consiglio di sorveglianza
Richard A. Gonzalez, Brett J. Hart, Edward J. Rapp, Frederick H. Waddell, Glenn F. Tilton, Melody B. Meyer, Rebecca B. Roberts, Robert J. Alpern, Roxanne S. Austin, Thomas Freyman, William H.L. Burnside
 

Dati aziendali

Name: AbbVie Inc.
Indirizzo: 1 North Waukegan Road,North Chicago, Illinois 60064-6400, USA
Telefono: +1-847-932-7900
Fax: -
E-mail: -
Internet: www.abbvie.com/
Industria: Healthcare
Settore: Pharmaceutical Industry
Sub settore: Pharmaceuticals
Fine dell'anno finanziario: 31/12
Flottante libero: 96.70%
Data dell'IPO: 02/01/2013

Rapporti con gli investitori

Name: Liz Shea
IR telefono: +1-847-935-2211
IR Fax: -
IR e-mail: liz.shea@abbvie.com

Principali azionisti

Altri
 
64.91%
Vanguard Group Inc
 
9.03%
Blackrock Inc.
 
7.88%
State Street Corporation
 
4.43%
JP Morgan Chase & Company
 
3.22%
Capital International Investors
 
2.44%
Geode Capital Management, LLC
 
1.98%
Capital Research Global Investors
 
1.84%
Morgan Stanley
 
1.77%
Altri
 
2.50%